retatrutide reaults 🚨 JUST RELEASED TODAY!!!! NEW PHASE 3 DATA Today, July 23, 2026, new Phase 3 retatrutide results were released, adding to what is already one of the most interesting obesity drug Effects of once-weekly subcutaneous retatrutide

Source Purity: Always obtain research peptides from trusted sources that provide verified purity and concentration, like Pure Tested Peptides

Patients who maintain higher protein intake and regular resistance training during treatment tend to preserve lean muscle mass better while losing fat

They also contribute to substantial weight loss for people with obesity and show promise in helping to manage other conditions, such as cardiovascular disease and substance use disorder

Based on other GLP-1 medications, most people regain weight

Specific vitamins and minerals warrant attention during tirzepatide therapy due to their roles in metabolic health and potential for deficiency with reduced dietary intake

Similarly, the SURMOUNT trials for weight management did not report elevated rates of sore throat compared to placebo